Logo image of TRMED.OL

THOR MEDICAL ASA (TRMED.OL) Stock Fundamental Analysis

Europe - OSL:TRMED - NO0010597883 - Common Stock

3.57 NOK
+0.22 (+6.57%)
Last: 10/31/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, TRMED scores 2 out of 10 in our fundamental rating. TRMED was compared to 73 industry peers in the Biotechnology industry. The financial health of TRMED is average, but there are quite some concerns on its profitability. TRMED does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TRMED had negative earnings in the past year.
In the past year TRMED has reported a negative cash flow from operations.
In the past 5 years TRMED always reported negative net income.
In the past 5 years TRMED always reported negative operating cash flow.
TRMED.OL Yearly Net Income VS EBIT VS OCF VS FCFTRMED.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

TRMED has a better Return On Assets (-4.73%) than 65.75% of its industry peers.
TRMED's Return On Equity of -5.61% is fine compared to the rest of the industry. TRMED outperforms 72.60% of its industry peers.
Industry RankSector Rank
ROA -4.73%
ROE -5.61%
ROIC N/A
ROA(3y)-146.91%
ROA(5y)-131.48%
ROE(3y)-270.57%
ROE(5y)-231.37%
ROIC(3y)N/A
ROIC(5y)N/A
TRMED.OL Yearly ROA, ROE, ROICTRMED.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

TRMED does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRMED.OL Yearly Profit, Operating, Gross MarginsTRMED.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K -100K

More info and screens

6

2. Health

2.1 Basic Checks

TRMED has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TRMED has more shares outstanding
TRMED has a worse debt/assets ratio than last year.
TRMED.OL Yearly Shares OutstandingTRMED.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
TRMED.OL Yearly Total Debt VS Total AssetsTRMED.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

TRMED has an Altman-Z score of 8.75. This indicates that TRMED is financially healthy and has little risk of bankruptcy at the moment.
TRMED's Altman-Z score of 8.75 is amongst the best of the industry. TRMED outperforms 83.56% of its industry peers.
TRMED has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.02, TRMED is doing good in the industry, outperforming 73.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 8.75
ROIC/WACCN/A
WACCN/A
TRMED.OL Yearly LT Debt VS Equity VS FCFTRMED.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

A Current Ratio of 8.87 indicates that TRMED has no problem at all paying its short term obligations.
TRMED has a better Current ratio (8.87) than 93.15% of its industry peers.
A Quick Ratio of 8.78 indicates that TRMED has no problem at all paying its short term obligations.
TRMED's Quick ratio of 8.78 is amongst the best of the industry. TRMED outperforms 93.15% of its industry peers.
Industry RankSector Rank
Current Ratio 8.87
Quick Ratio 8.78
TRMED.OL Yearly Current Assets VS Current LiabilitesTRMED.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 94.44% over the past year.
EPS 1Y (TTM)94.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.51%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRMED.OL Yearly Revenue VS EstimatesTRMED.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 200K 400K 600K
TRMED.OL Yearly EPS VS EstimatesTRMED.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRMED. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRMED. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRMED.OL Price Earnings VS Forward Price EarningsTRMED.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TRMED indicates a somewhat cheap valuation: TRMED is cheaper than 71.23% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 193.43
TRMED.OL Per share dataTRMED.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRMED!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THOR MEDICAL ASA

OSL:TRMED (10/31/2025, 7:00:00 PM)

3.57

+0.22 (+6.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-28 2024-02-28/amc
Earnings (Next)N/A N/A
Inst Owners1.15%
Inst Owner ChangeN/A
Ins Owners1.22%
Ins Owner ChangeN/A
Market Cap1.26B
Revenue(TTM)N/A
Net Income(TTM)-26561000
Analysts34.29
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.66
P/tB 7.37
EV/EBITDA 193.43
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0
BVpS1.34
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.73%
ROE -5.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-146.91%
ROA(5y)-131.48%
ROE(3y)-270.57%
ROE(5y)-231.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 1.53
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.87
Quick Ratio 8.78
Altman-Z 8.75
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80.18%
EPS Next Y50.51%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y97.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y88.7%
OCF growth 3YN/A
OCF growth 5YN/A

THOR MEDICAL ASA / TRMED.OL FAQ

Can you provide the ChartMill fundamental rating for THOR MEDICAL ASA?

ChartMill assigns a fundamental rating of 2 / 10 to TRMED.OL.


What is the valuation status for TRMED stock?

ChartMill assigns a valuation rating of 1 / 10 to THOR MEDICAL ASA (TRMED.OL). This can be considered as Overvalued.


What is the profitability of TRMED stock?

THOR MEDICAL ASA (TRMED.OL) has a profitability rating of 1 / 10.


What is the expected EPS growth for THOR MEDICAL ASA (TRMED.OL) stock?

The Earnings per Share (EPS) of THOR MEDICAL ASA (TRMED.OL) is expected to grow by 50.51% in the next year.